You are here

  • Home
  • Archive
  • Volume 13, Issue 10
  • Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain

Article metrics

Article menu

Download PDFPDF

Novel treatment (new drug/intervention; established drug/procedure in new situation)
Case report
Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain

 

Online download statistics by month:

Online download statistics by month: October 2020 to April 2024

AbstractFullPdf
Oct 20207922527
Nov 202048735
Dec 202011631
Jan 202111921
Feb 20218922
Mar 202110353
Apr 202111023
May 20212646
Jun 2021415
Jul 2021431
Aug 2021422
Sep 2021441
Oct 20213621
Nov 20216532
Dec 20212611
Jan 20223200
Feb 20223911
Mar 20226601
Apr 20222912
May 20224000
Jun 20224843
Jul 20223830
Aug 20224420
Sep 20224511
Oct 20224850
Nov 20222010
Dec 20224130
Jan 20235600
Feb 20234100
Mar 20233240
Apr 20233110
May 20237520
Jun 20234700
Jul 20232820
Aug 20232300
Sep 20231110
Oct 20232500
Nov 20234010
Dec 2023800
Jan 20242731
Feb 20245400
Mar 20248301
Apr 20243300
Total30899771